Idiopathic pulmonary fibrosis market seen doubling by 2030

Allied Market Research projects the global idiopathic pulmonary fibrosis market will grow from $3.12 billion in 2020 to $6.16 billion by 2030, driven by higher cancer incidence, reimbursement support and smoking rates. Pirfenidone leads the drug market, retail pharmacies remain the top channel and Asia-Pacific is expected to grow fastest.

Why it matters: - The idiopathic pulmonary fibrosis market is projected to nearly double by 2030, signaling continued demand for treatments and related distribution channels. - Growth in the market could shape investment priorities for drug makers, pharmacies and healthcare providers focused on chronic lung disease.

What happened: - Allied Market Research published a global forecast for the idiopathic pulmonary fibrosis market covering 2021-2030. - The market was valued at $3.12 billion in 2020 and is projected to reach $6.16 billion by 2030. - The report forecasts a 7.0% compound annual growth rate over the period. - The study covers drug type and distribution channel, with separate regional analysis.

The details: - The report breaks the market into nintedanib and pirfenidone by drug type. - The report segments distribution into hospital pharmacies, retail pharmacies and online providers. - Pirfenidone accounted for about three-fourths of the market in 2020 and is expected to keep the lead through 2030. - Pirfenidone is projected to post the fastest drug-type CAGR at 7.2% from 2021 to 2030. - The growth in pirfenidone is linked to broader adoption of drugs such as Esbriet and Pirespa. - Retail pharmacies held nearly half the market in 2020 and are expected to remain the leading channel. - Online providers are projected to grow the fastest among channels, with an 8.5% CAGR, helped by discounts and access to multiple drugs on one platform. - North America held more than two-fifths of the global market in 2020 and is expected to remain the top revenue region by 2030. - Asia-Pacific is projected to grow fastest by region, with an 8.9% CAGR. - The report cites rising cancer incidence, favorable reimbursement policies and increased cigarette smoking as market drivers. - The report identifies the lack of proper treatment options as a restraint. - The report points to more pipeline drugs and untapped demand in developing countries as future opportunities. - The companies listed in the market landscape include AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GNI Group, Roche/Genentech, Shionogi, Mission Therapeutics, Biogen, Galapagos and FibroGen. - Sample PDF report is available from Allied Market Research. - Purchase inquiry is also available.

Between the lines: - The forecast suggests the market is being shaped by both higher diagnosis and broader commercial support, not just drug innovation. - Faster growth in online providers hints at a shift in how patients may access specialty respiratory medicines. - Regional growth patterns suggest mature markets like North America will keep revenue leadership while Asia-Pacific expands on lower current penetration and improving healthcare capacity.

What's next: - Pipeline development and market expansion in developing countries are likely to be key watchpoints through 2030. - Drug makers and distributors may keep competing on access, reimbursement and channel reach as the market expands. - Regional momentum in Asia-Pacific could attract additional investment in research and commercialization.

The bottom line: - Idiopathic pulmonary fibrosis remains a small but growing specialty market, with treatment access and regional expansion likely to drive the next phase of growth.